Analysis of the characteristics of Age-related Macular Degeneration
Article Sidebar
Main Article Content
Abstract
Objective: To analyze the characteristics of Age-Related Macular Degeneration (AMD). Bibliographic review: AMD is a progressive degenerative disease of the retina that affects the central macular region, often leading to progressive vision loss. There are around 170 million people affected with the disease worldwide, which makes this disease the third leading cause of blindness in the world. Clinically, AMD is classified into early stage (stages 1 and 2), intermediate (stage 3) and late stage (stage 4), with the final stage divided into wet and dry AMD. Final considerations: AMD is the most common cause of incurable visual impairment in developed countries and is age-related with an average onset around 60 years, in addition to a high burden for the individual and society. It is essential to prevent the disease by promoting a healthier lifestyle. There is no treatment for dry AMD and for wet AMD the therapy is intravitreal injection of anti-vascular endothelial growth factor agents which is able to reduce blindness and the density of choroid capillaries.
Article Details
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
References
2. BLASIAK J, et al. Interplay between aging and other factors of the pathogenesis of age-related macular degeneration. Ageing Res Rev, 2022; 81: 101735.
3. CHO YK, et al. Medication Trends for Age-Related Macular Degeneration. Int J Mol Sci, 2021; 22(21): 11837.
4. COLIJN JM, et al. Genetic Risk, Lifestyle, and Age-Related Macular Degeneration in Europe: The EYE-RISK Consortium. Ophthalmology, 2021; 128(7): 1039-1049.
5. DENG Y, et al. Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis, 2021; 9(1): 62-79.
6. FABRE M, et al. Recent Advances in Age-Related Macular Degeneration Therapies. Molecules, 2022; 27(16): 5089.
7. FERNANDES AR, et al. Exudative versus Nonexudative Age-Related Macular Degeneration: Physiopathology and Treatment Options. Int J Mol Sci, 2022; 23(5): 2592.
8. FLORES R, et al. Age-Related Macular Degeneration: Pathophysiology, Management, and Future Perspectives. Ophthalmologica, 2021; 244(6): 495-511.
9. GARCIA-GARCIA J, et al. Pathophysiology of Age-Related Macular Degeneration: Implications for Treatment. Ophthalmic Res, 2022; 65(6): 615-636.
10. HEESTERBEEK TJ, et al. Risk factors for progression of age-related macular degeneration. Ophthalmic Physiol Opt, 2020; 40(2): 140-170.
11. HSU MH, et al. Gout as a Risk Factor for Age-Related Macular Degeneration in Taiwanese Adults-A Population-Based Study in Taiwan. Int J Environ Res Public Health, 2022; 19(16): 10142.
12. JUNG W, et al. Association between Age-Related Macular Degeneration and the Risk of Diabetes Mellitus: A Nationwide Cohort Study. Biomedicines, 2022; 10(10): 2435.
13. KUAN V, et al. Association of Smoking, Alcohol Consumption, Blood Pressure, Body Mass Index, and Glycemic Risk Factors With Age-Related Macular Degeneration: A Mendelian Randomization Study. JAMA Ophthalmol, 2021; 139(12): 1299-1306.
14. LOMBARDO M, et al. Challenges in Age-Related Macular Degeneration: From Risk Factors to Novel Diagnostics and Prevention Strategies. Front Med (Lausanne), 2022; 9: 887104.
15. MA HH, LIUTKEVICIENE R. Age-Related Macular Degeneration: What Do We Know So Far? Acta Med Litu, 2021; 28(1): 36-47.
16. NASHINE S. Potential Therapeutic Candidates for Age-Related Macular Degeneration (AMD). Cells, 2021; 10(9): 2483.
17. NITTALA MG, et al. Risk Factors for Progression of Age-Related Macular Degeneration: Population-Based Amish Eye Study. J Clin Med, 2022; 11(17): 5110.
18. RIM PHH, et al. Correlation between genetic and environmental risk factors for age-related macular degeneration in Brazilian patients. PLoS One, 2022; 17(6): e0268795.
19. RINNINELLA E, et al. The Role of Diet, Micronutrients and the Gut Microbiota in Age-Related Macular Degeneration: New Perspectives from the Gut⁻Retina Axis. Nutrients, 2018; 10(11): 1677.
20. SCHULTZ NM, et al. Global Burden of Dry Age-Related Macular Degeneration: A Targeted Literature Review. Clin Ther, 2021; 43(10): 1792-1818.
21. STAHL A. The Diagnosis and Treatment of Age-Related Macular Degeneration. Dtsch Arztebl Int, 2020; 117(29-30): 513-520.
22. TAN W, et al. The Role of Inflammation in Age-Related Macular Degeneration. Int J Biol Sci, 2020; 16(15): 2989-3001.
23. THOMAS CJ, et al. Age-Related Macular Degeneration. Med Clin North Am, 2021; 105(3): 473-491.
24. VYAS A, et al. The Need for Artificial Intelligence Based Risk Factor Analysis for Age-Related Macular Degeneration: A Review. Diagnostics (Basel), 2022; 13(1): 130.
25. YIP JLY, et al. Socioeconomic risk factors and age-related macular degeneration in the UK Biobank study. BMJ Open Ophthalmol, 2021; 6(1): e000585.
26. YUK JS, HWANG JH. Menopause and the Risk of Developing Age-Related Macular Degeneration in Korean Women. J Clin Med, 2022; 11(7): 1899.
27. WANG Y, et al. Global Incidence, Progression, and Risk Factors of Age-Related Macular Degeneration and Projection of Disease Statistics in 30 Years: A Modeling Study. Gerontology, 2022; 68(7): 721-735.